SCHEMBL2075445

SCHEMBL2075445

Nc1ccc(-c2cn(C3CCCC3)c3ncnc(Cl)c23)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 11/20 0.63
EGFR P00533 9/20 0.63
ABL1 P00519 8/20 0.63
ABL2 P42684 8/20 0.63
LCK P06239 5/20 0.57
KDR P35968 5/20 0.57
TEK Q02763 4/20 0.57
LYN P07948 2/20 0.57
KDM4E B2RXH2 1/20 0.57
MEN1 O00255 1/20 0.57
RGS12 O14924 1/20 0.57
NPC1 O15118 1/20 0.57
GMNN O75496 1/20 0.57
ALDH1A1 P00352 1/20 0.57
LMNA P02545 1/20 0.57
TP53 P04637 1/20 0.57
CYP1A2 P05177 1/20 0.57
FYN P06241 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20351599 0.95 SRC (0.61) SRCEGFRABL1ABL2LCK
SCHEMBL20351793 0.89 SRC (0.60) SRCEGFRABL1ABL2LCK
SCHEMBL28669572 0.89 EGFR (0.56) SRCEGFRABL1ABL2LCK
SCHEMBL28669568 0.89 EGFR (0.56) SRCEGFRABL1ABL2LCK
SCHEMBL20351775 0.89 SRC (0.52) SRCEGFRABL1ABL2LCK
SCHEMBL20351711 0.88 SRC (0.52) SRCEGFRABL1ABL2LCK
SCHEMBL18044541 0.87 SRC (0.81) SRCEGFRABL1ABL2LCK
SCHEMBL2072372 0.87 SRC (0.60) SRCEGFRABL1ABL2LCK
SCHEMBL20351548 0.86 SRC (0.49) SRCEGFRABL1ABL2LCK
SCHEMBL20351610 0.85 RIPK2 (0.47) SRCEGFRABL1ABL2LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018121228-A1 COMPOUND HAVING AXL INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF 中国科学院上海药物研究所 2018-07-05 WO disclosed
EP-3067356-B1 PYRROLO PYRIMIDINE DERIVATIVE ONO PHARMACEUTICAL CO (JP) 2018-07-04 EP disclosed
US-9586967-B2 Pyrrolo pyrimidine derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2017-03-07 US disclosed
US-20160264579-A1 PYRROLO PYRIMIDINE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2016-09-15 US disclosed
EP-3067356-A1 PYRROLO PYRIMIDINE DERIVATIVE ONO Pharmaceutical Co., Ltd. (JP) 2016-09-14 EP disclosed
US-7863444-B2 4-aminopyrrolopyrimidines as kinase inhibitors ABBOTT LABORATORIES (US) 2011-01-04 US disclosed
EP-1114052-B1 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS ABBOTT GMBH & CO KG (DE) 2005-11-16 EP disclosed
US-20030187001-A1 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264579-A1 PYRROLO PYRIMIDINE DERIVATIVE AXL, FLT3, TYRO3 SRC 26/4885EGFR 80/4885ABL1 39/4885
US-20030187001-A1 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS LCK, PPP5C, DUSP1 SRC 89/4885EGFR 294/4885ABL1 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.